What is it about?
This a study detailing an open and enrolling protocol for young adult patient with malignant glioma and diffuse midline glioma. Our study is focused on safety and ability to measure chemotherapy, abemaciclib, within the tumor over time after surgery, all with the purpose of increasing our understanding of disease response.
Featured Image
Photo by Robina Weermeijer on Unsplash
Why is it important?
This is important because the blood-brain barrier stops good therapy from reaching these aggressive brain tumors and our study is looking at how much drug gets to the tumor as well as for how long and to what regions.
Perspectives
It is an enriching study that will allow patients to become more knowledgeable about their glioma pharmacokinetics and treatment response in real time.
Sadhana Jackson
National Institutes of Health
Read the Original
This page is a summary of: Clinical protocol: Feasibility of evaluating abemaciclib neuropharmacokinetics of diffuse midline glioma using intratumoral microdialysis, PLoS ONE, September 2023, PLOS,
DOI: 10.1371/journal.pone.0291068.
You can read the full text:
Resources
Contributors
The following have contributed to this page
